Beam Therapeutics
BEAM · NASDAQ · Health Care · Biological Products, (No Diagnostic Substances)
Biological Products, (No Diagnostic Substances) company based in Cambridge, Ma.
Example public filing
Duquesne Family Office opened a new position $5.27M
Duquesne Family Office opened a new position in Beam Therapeutics, per its Q2 2026 13F.
- 154K
- Shares reported
- 0.10%
- Disclosed portfolio weight
- $5.27M
- Reported value
- Holdings as of
- Jun 30, 2026
- Filed
- Aug 14, 2026
Data as of Oct 11, 2026. A real record from the official source, chosen as the most recent insider trade or, failing that, the most recent filing of another kind; not a recommendation.
On file for BEAM, last 12 months
- 2
- Insider filings
- 0
- Congress trades
- 13
- Fund positions
- 0
- Federal contracts
Records OQRO holds, counted by their date; a 13F position is counted once per quarter it is reported.
Insider buying and selling since 2020
Insiders of Beam Therapeutics reported 0 open-market purchases and 213 sales since 2020; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | 1×1 trade |
| 2025 | — | 15×15 trades |
| 2024 | — | 20×20 trades |
| 2023 | — | 27×27 trades |
| 2022 | — | 52×52 trades |
| 2021 | — | 79×79 trades |
| 2020 | — | 19×19 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. The amounts, the people and every filing are in OQRO Pro.
See the full picture with OQRO Pro.
15 records for Beam Therapeutics in the last 12 months, each linked to its filing. Full histories, the screener, alerts for the companies you follow and Ask OQRO.
Latest disclosures
Secure payment by Stripe. Renews every month until you cancel; cancel anytime from your account. No free trial.
Public previews are free. Full research requires Pro. No free trial.
What this page holds
- Insider trades and planned sales
- Politician trades (House and Senate)
- Fund holdings from 13F filings
- Federal contracts, lobbying and short selling
- Full history and context, with a link to every filing
What OQRO is
OQRO reads the public record for US-listed companies — insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings, and federal contract awards — and puts each one in plain words next to the filing it came from. It describes what was disclosed. It does not give investment advice or tell you what to buy.
Want to see real filings before you pay? The home page shows live ones, free, with the link to each source document.
Questions about Beam Therapeutics insider trading
Have Beam Therapeutics insiders bought shares recently?
No open-market purchase by an insider of Beam Therapeutics is on record in SEC filings since 2006.
How often do Beam Therapeutics insiders buy and sell shares?
Since 2020, Beam Therapeutics insiders reported 0 open-market purchases and 213 sales on Forms 4 and 5.
Do members of Congress trade BEAM?
No trade in Beam Therapeutics (BEAM) was disclosed by a member of Congress in the last 12 months.
When does Beam Therapeutics report its next results?
Beam Therapeutics's next results are expected on Nov 2, 2026. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.